What does license and other revenues — receivables mean?

This metric captures the aggregate balance of accounts receivable specifically attributable to the licensing and other revenue segment. It reflects the timing difference between the recognition of revenue from contractual milestones or royalties and the actual receipt of cash. Analyzing this balance is essential for evaluating the cash conversion cycle and the credit quality of the company's licensing partners.

BioCryst Pharmaceuticals BCRX License and other revenues — Receivables

Similar metrics at other companies

ARDXLicensing revenue — Payment

$15M—

SHAKLicensing receivables, net of allowance for doubtful accounts — Contract with customer, asset, net

$6.12M+7.4%

INVALicense And Other Revenue — Revenue

$1.46M+167%

CHDNOther receivables — Accounts receivable

$31M+15.7%

ACIWLicense — Revenue

$88.04M+4.2%

CPRXLicense And Other Revenue — Revenue

$47K+124%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.54B+52.3%

Enterprise value$2.78B+46.7%

P/S2.9×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ReceivablesNetCurrent.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's license and other revenues — receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's license and other revenues — receivables?: BioCryst Pharmaceuticals (BCRX) reported license and other revenues — receivables of $3.98M in Q4 2025.
What does license and other revenues — receivables mean?: This metric captures the aggregate balance of accounts receivable specifically attributable to the licensing and other revenue segment. It reflects the timing difference between the recognition of revenue from contractual milestones or royalties and the actual receipt of cash. Analyzing this balance is essential for evaluating the cash conversion cycle and the credit quality of the company's licensing partners.